Centre for Commercialization of Regenerative Medicine

Michael May is President and CEO, overseeing strategy and operations at CCRM. His background includes leading the organization's commercialization efforts, including company creation and partnership development. The organization does not publicly disclose an investment committee structure.

CCRM is a non-profit commercialization catalyst, distinct from both family offices and traditional venture capital. It operates as a collaborative platform that pools stakeholders from academia, industry, and government to develop and scale regenerative medicine companies.

CCRM creates and scales companies through its translational platforms and infrastructure, a hybrid of service provision and de facto company building. Its OmniaBio GMP facility and CCVP platform represent capital-intensive assets that support cell and gene therapy development.

CCRM works primarily at the pre-commercial and early-stage interface, bridging academic research and industry. It focuses on technologies that address bottlenecks in regenerative medicine commercialization, often supporting ventures before they reach typical venture capital investment stages.

CCRM co-founded the Canadian Advanced Therapies Training Institute (CATTI) in 2021 with CellCAN to address the biomanufacturing talent shortage. Michael May sits on CATTI's board, and CATTI's CEO Vanessa Laflamme and board chair William Brock leverage CCRM's network. CATTI operates as a separate entity with its own leadership.

CCRM focuses exclusively on regenerative medicine, cell and gene therapies, and related advanced therapy technologies. It does not invest outside this therapeutic modality. Its DeepTech Bio Lab also incorporates AI, quantum, and data technologies to accelerate cell and gene therapy development.

Yes, the CCRM Foundation serves as a strategic philanthropy arm for advanced therapies. It is separate from CCRM's core commercialization and training activities, with a distinct philanthropic mandate.